Phathom (PHAT) Q3 2026 Earnings Call Transcript
Phathom (PHAT) reported Q3 2026 net revenues of $84.7M, operating profit of $5.8M, and cash from operations of $2.1M. The company highlighted strong prescription growth for VOQUEZNA, with 2M+ prescriptions filled since launch. Phathom reiterated its full-year revenue guidance of $310M-$325M and discussed legal action by BDR Pharmaceuticals challenging VOQUEZNA's exclusivity period.
How this was made

The 30-second read
Why it matters
Earnings beat and guidance suggest near-term price appreciation, but litigation risk remains.
Market read
First earnings release provides actionable data for traders; potential upside balanced by legal risk.
What to watch
Potential regulatory risk from ongoing exclusivity litigation could affect future sales.
Background
Phathom reported Q3 results, highlighted prescription milestones, and provided full-year revenue guidance.
Ticker impact
Q3 2026 earnings disclosed net revenue $84.7M, operating profit $5.8M and full-year guidance $310M-$325M.
likely upward pressure as investors price in revenue beat and guidance.
First disclosure of earnings and guidance provides fresh material for traders.
Market effects
Strengthens outlook for GERD treatment sector and related pharma peers.
U.S. biotech market may see modest lift.
Limited to pharma/biotech investors.
Counterpoint
Growth may be unsustainable if prescription volume slows after initial launch momentum.
Key entities
- CompanyPhathom
Biopharma developing VOQUEZNA for GERD.
- CompanyBDR Pharmaceuticals
Filed suit challenging VOQUEZNA exclusivity.


